相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 库存:
53
- 英文名:
SNS-314 Mesylate
- CAS号:
1146618-41-8
- 供应商:
上海莼试
- 保存条件:
Store at -20°C
- 规格:
10mM (in 1mL DMSO) 5mg 10mg 50mg 200mg
分子式:C18H15ClN6OS2.CH4O3S

分子量:527.04
溶解度:≥ 26.35 mg/mL in DMSO
储存条件:Store at -20°C
General tips:For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping Condition:Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request
SNS-314 is an ATP-competitive and selective inhibitor of aurora kinases with IC50 values of 9 nM, 31 nM and 3 nM against Aurora A, Aurora B and Aurora C, respectively [1 and 2].Aurora kinases are serine/threonine kinases that regulate mitosis of cells. They are found to be associated with the onset and propagation of cancer and over-expressed in various tumor cell lines such as melanoma, ovarian, colon, pancreatic and breast tumors. Therefore, aurora kinases are being evaluated as potential targets in cancer therapy .As a potent inhibitor of aurora kinase, SNS-314inhibited proliferation in a broad panel of tumor cell lines and showed potent anti-tumor activity in mice bearing HCT116 xenografts. Besides that, a mechanism of its action was found to be inhibiting the phosphorylation of histoneH3 at Ser10 [1 and 2].In the FRET-based biochemical assay, SNS-314inhibited Aurora A, B and C with IC50 values of 9, 31 and 3 nM, respectively. When tested against a panel of 219 kinases, SNS-314 only inhibited 24 kinases of them by 65% or above. It suggested that SNS-314 was a selective inhibitor of aurora kinase. In cell-based assays, SNS-314 blocked the proliferation of cancer cells with IC50 value in the range from 1.8 nM (A2780) to 24 nM (HT29). In HCT-116 cells, SNS-314 treatment for 16 hours resulted in distinct cell-cycle defects [2].In human tumor xenograft mouse models, administration of SNS-314 exerted significant anti-tumor activities against xenografts of PC-3, H1299, A2780, MDA-MB-231 and A375 cells. The TGI value achieved between 54% and 91% when the dose was 170 mg/kg. The administration also caused a profound and sustained inhibition of pHH3 which was a substrate of Aurora B [2].
商品属性:
| 货号 | CS-01Y67609 | 规格 | 10mM (in 1mL DMSO) 5mg 10mg 50mg 200mg |
| CAS号 | 1146618-41-8 | 分子量 | 527.04 |
| 含量 | >98.00% | 别名 | |
| 分子式 | C18H15ClN6OS2.CH4O3S | 化学名 | 1-(3-chlorophenyl)-3-[5-[2-(thieno[3,2-d]pyrimidin-4-ylamino)ethyl]-1,3-thiazol-2-yl]urea;methanesulfonic acid |
| 产地 | 国产 | 用途 | 仅供科研研究实验 |
抗逆滴加序列
每次向板内滴加抗原时,移液器滴头要与平面45度悬空,不要触碰到孔内的液体,由后向前依次滴加(即浓度由低往高滴加)。
抗感染反应期
抗原抗体在室温20~25℃下,必须反应30min以上,若环境温度低于室温,可将微量反应板置于恒温培养箱中,使二者充分反应。
旅游温度
磷酸盐缓冲液的pH值要在高压灭菌后进行滴定,往往在高压后pH值会有所改变,所以高压后再调一次pH值更为准确。磷酸盐缓冲液一经使用保存期不要超过3周。当pH<5.8时,红细胞会产生自凝现象;当pH>7.8时,图形洗脱加快,易造成肉眼观察产生误差;p H=7.2时,红细胞沉降最充分,图形最清晰。
当滴注 1%红细胞悬液时,应经常摇晃红细胞悬液,使红细胞均匀地分布在磷酸缓冲液中,以防止红细胞下降。
反应时间及温度
加入鸡红血球之后,反应板在室温(20~25℃)静置30~40min,对照孔血球下沉于孔底,即可判定结果。若室温达不到实验要求,需相应调整反应时间。当环境温度低于4℃时,红细胞发生自凝;高于37℃时,会发生反应物分离和红细胞溶血。
公司正在出售的产品:
| 核受体相互作用蛋白3封闭多肽 | 恶性纤维组织细胞瘤封闭多肽 |
| 凋亡加强结构域蛋白17/INCA封闭多肽 | MFSD7蛋白抗体 |
| 核受体共激活因子5封闭多肽 | 周期蛋白结合蛋白抗体 |
| 脂质运载蛋白封闭多肽 | 热休克转录因子2抗体 |
| 卷曲螺旋结构域蛋白144A封闭多肽 | 磷酸化原癌基因蛋白18 |
| 泛酸激酶2封闭多肽 | α1微球蛋白单克隆抗体 |
| 磷酸化荷尔蒙敏感脂肪酶封闭多肽 | 磷酸化KLF5抗体 |
| 电压门控钠通道SCN3α蛋白/Na+ CP type IIIα封闭多肽 | FBXW8蛋白抗体 |
| 葡萄糖-6磷酸转运蛋白封闭多肽 | 软骨肉瘤相关蛋白2抗体 |
| 生长抑素多肽 | 富含半胱氨酸分泌蛋白3抗体 |
| 磷酸化细胞凋亡信号调节激酶1封闭多肽 | 瞬时受体电位离子通道蛋白5抗体(M亚家族) |
| 组织相容性复合体α封闭多肽 | 双特异性磷酸酶抗体21抗体 |
| 聚磷酸肌醇磷酸酶5B封闭多肽 | SNS-314 Mesylate紧密连接蛋白15抗体 |
| 高迁移率族蛋白N3封闭多肽 | 磷酸化细胞周期检查控制蛋白质抗体 |
| 5号染色体开放阅读框22抗体 | EB病毒核抗原-3A抗体 |
1.本蛋白酶抑制剂混合物为100×的储存液,使用时按照1:100的比例加入到裂解液中(例如,1ml裂解液中加入10μl蛋白酶抑制剂混合物),混匀后即可使用。根据需要,0.5M的EDTA也按照1:100的比例加入到裂解液中(如用于检测金属蛋白酶活性,则不宜添加EDTA)。含有蛋白酶抑制剂混合物的裂解液宜现用现配,不宜配制后冻存待后续使用。
2. 待所需的抑制剂添加完毕混匀后,就可以开始进行哺乳动物组织的裂解和蛋白提取。
风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验Detection of BCR-ABL Mutations and Resistance to Imatinib Mesylate
The major mechanism of imatinib resistance for patients with chronic myeloid leukemia (CML) is clonal expansion of leukemic cells with mutations in the Bcr-Abl fusion tyrosine kinase that reduce the capacity of imatinib to inhibit kinase
(从句中)可以使用现在时态或过去时态。值得注意的是,这两种动词时态之间的区别主要在于:现在时一般用于表达事实陈述或一般真理,而过去时则用于表达过去发生的事情(也许是短暂的),但没有被证明是永远真实的(即普适性的事实)。请看下面的例子:Our results demonstrate that SNS1 is phosphorylated by OST1. (我们的研究结果证明,SNS1 被 OST1 磷酸化了。)Our results demonstrate that SNS
-4 and C-5 centers ( 3 ). After formatron of the mesylate, from the recycled material the amine function is introduced through azrde displacement of the mesylate, followed by reduction ( 4 ) and protectron with the t -BOC group. Finally, the lactone
技术资料暂无技术资料 索取技术资料









